Translating Electromagnetic Signals into Non-Invasive Therapeutics
Technology
Neurophysiologic Electromagnetic Stimulation (nEMS)
Therapy AI-Driven Innovation for Restoring Insulin Secretion
Biomolecular LLC has developed a patented therapeutic platform that combines artificial intelligence with neurophysiologic electromagnetic stimulation (nEMS) to restore pancreatic β-cell function. This non-invasive approach offers a transformative alternative to traditional drug-based diabetes treatments.
How It Works
Our nEMS therapy uses targeted electromagnetic pulses to stimulate neurophysiologic pathways that regulate pancreatic function. AI algorithms personalize stimulation protocols based on patient-specific data, optimizing therapeutic outcomes and minimizing side effects.
Key Features:
- Non-invasive and drug-free
- AI-guided treatment personalization
- Restores natural insulin secretion
- Targets both Type 1 and Type 2 diabetes mechanisms
Scientific Foundation
Our technology is built on decades of research in electrophysiology, biomedical engineering, and artificial intelligence. Inspired by pioneers like Luigi Galvani and Robert Bárány, we apply classical bioelectric principles to modern therapeutic design.
Scientific Pillars:
- Electrophysiologic modulation of β-cell activity
- Machine learning for adaptive therapy control
- Bioelectronic device engineering and sensor integration
Development Status
- Market-ready prototype completed
- Preclinical validation underway
- Seeking federal funding for clinical trials and regulatory approval
- Aligned with NIH, NSF, and DoD research priorities
Data adapted from U.S. Patent No. 8,457,745 – Method for Pancreatic β-cell Control (https://patents.google.com/patent/US8457745B1/en)
We’re actively seeking FDA approval to proceed to a clinical trial. Biomolecular LLC is further advancing its patented nEMS device by integrating it with an AI algorithm for precise anatomical placement of stimulating electrodes.
AI-driven nEMS Technology
We’re seeking to future-proof our novel therapeutic Device with AI integration.
How It Works
Our nEMS therapy uses targeted electromagnetic pulses to stimulate neurophysiologic pathways that restore the neurophysiologic function of pancreatic beta cells.
The restored function of β cells’ calcium ion (Ca2+)channels provides functional restoration of insulin secretion.
AI algorithms personalize stimulation protocols based on patient-specific data, optimizing therapeutic outcomes and therapy adaptation.
Key Features:
- Non-invasive therapy
- Dual targeting of neurophysiologic impairment of both Type 1 and Type 2 diabetes
- Restores natural insulin secretion, eliminating the need for insulin therapy
- AI-guided treatment precision, personalization and therapy adaptation
Scientific Foundation
Our AI-driven nEMS technology is built on decades of research in electrophysiology, biomedical engineering, and artificial intelligence. Inspired by pioneers like Luigi Galvani and Robert Bárány, we apply classical bioelectric principles to modern therapeutic design.
Our Scientific Pillars:
- Electrophysiologic modulation of β-cell activity
- Machine learning for adaptive therapy control
- Bioelectronic device engineering and sensor integration
Development Status
- Market-ready prototype completed
- Preclinical validation underway
- Seeking federal funding for clinical trials and regulatory approval
- Aligned with NIH, NSF, and DoD research priorities